815575-86-1 Usage
Description
1-PIPERIDINECARBOXYLIC ACID, 3-CHLORO-4-OXO-, 1,1-DIMETHYLETHYL ESTER, also known as 3-Chloro-4-oxo-piperidine-1-carboxylic Acid tert-Butyl Ester, is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by its piperidine ring structure, with a chloro and keto group at the 3rd and 4th positions, respectively, and a 1,1-dimethylethyl ester group attached to the carboxylic acid moiety.
Uses
Used in Pharmaceutical Industry:
1-PIPERIDINECARBOXYLIC ACID, 3-CHLORO-4-OXO-, 1,1-DIMETHYLETHYL ESTER is used as a reactant in the preparation of piperidines as antibacterial agents. It plays a crucial role in the synthesis of these compounds, which are known for their broad-spectrum antimicrobial properties and are used to treat various bacterial infections.
In the pharmaceutical industry, 3-Chloro-4-oxo-piperidine-1-carboxylic Acid tert-Butyl Ester is utilized in the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of novel piperidine-based compounds with potential applications in medicine, such as antibiotics, antifungals, and antiprotozoals. The versatility of this compound makes it a valuable asset in the ongoing search for new and effective treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 815575-86-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,5,5,7 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 815575-86:
(8*8)+(7*1)+(6*5)+(5*5)+(4*7)+(3*5)+(2*8)+(1*6)=191
191 % 10 = 1
So 815575-86-1 is a valid CAS Registry Number.
815575-86-1Relevant articles and documents
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)
Basarab, Gregory S.,Hill, Pamela J.,Garner, C. Edwin,Hull, Ken,Green, Oluyinka,Sherer, Brian A.,Dangel, P. Brian,Manchester, John I.,Bist, Shanta,Hauck, Sheila,Zhou, Fei,Uria-Nickelsen, Maria,Illingworth, Ruth,Alm, Richard,Rooney, Mike,Eakin, Ann E.
supporting information, p. 6060 - 6082 (2014/08/18)
AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.